Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Allen & Hanburys Ltd
Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Telephone: +44 (0)800 221 441
Fax: +44 (0)208 990 4328
Medical Information e-mail: customercontactuk@gsk.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 17/05/2012
SPC Serevent Diskhaler

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 17/05/2012 and displayed until Current
Reasons for adding or updating:
  • Change to section 1 -Name of the Medicinal product
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
Updated on 20/08/2009 and displayed until 17/05/2012
Reasons for adding or updating:
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 10 date of revision of the text
Updated on 15/07/2008 and displayed until 20/08/2009
Reasons for adding or updating:
  • Change to section 5.1 - Pharmacodynamic Properties
Updated on 19/10/2007 and displayed until 15/07/2008
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Updated on 18/03/2004 and displayed until 19/10/2007
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic Indications
  • Change to section 4.4 - Special Warnings and Precautions for Use
Updated on 06/11/2003 and displayed until 18/03/2004
Reasons for adding or updating:
  • Change to section 2 - qualitative and quantitative composition
  • Change to section 4.3 - Contra-indications
  • Change to section 6.1 - List of Excipients
Updated on 29/09/2003 and displayed until 06/11/2003
Reasons for adding or updating:
  • Change to section 2 - qualitative and quantitative composition
  • Change to section 4.3 - Contra-indications
  • Change to section 6.1 - List of Excipients
Updated on 17/08/2001 and displayed until 29/09/2003
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 09/04/2001 and displayed until 17/08/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 22/03/2001 and displayed until 09/04/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 21/09/2000 and displayed until 22/03/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/09/1999 and displayed until 21/09/2000
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
  salmeterol xinafoate